Fig. 7: Exploration of the combined effect of GINS2 inhibitor and TMZ.

A Two potential inhibitors of GINS2 were screened by CMap database. B CCK8 assay to detect the IC₅₀ of Pal, BIX-02189 in glioma cell lines U251 and LN229. C U251 and LN229 were treated with 10 μM Pal time gradient and Western blotting detected protein levels of GINS2, EGR1 and ECT2. D Concentration gradient of Pal treated U251 and LN229 for 72 h. Western blotting assays were performed to detect the protein levels of GINS2, EGR1 and ECT2. E U251 and LN229 were treated with 5 μM BIX time gradient and Western blotting detected protein levels of GINS2, EGR1 and ECT2. F A concentration gradient of BIX treated U251 and LN229 for 72 h. Western blotting assays were performed to detect the protein levels of GINS2, EGR1 and ECT2. G U251/LN229 were treated with different concentrations of Pal in combination with different concentrations of TMZ, and CCK8 was used to assess cell viability and CompuSyn software was used to calculate CI. H U251/LN229 cells were treated with different concentrations of BIX in combination with different concentrations of TMZ, and CCK8 was used to assess cell viability and CompuSyn software was used to calculate CI. I CCK8 experiments to assess cell viability after treatment of U251/LN229 with TMZ alone, Pal or a combination of the two drugs in a time gradient. J Cell viability was assessed in CCK8 assays after treatment of U251/LN229 with TMZ alone, BIX-02189 or a two-drug combination time gradient. Pal Palbociclib, BIX BIX-02189, CI Combination index, NS No significance. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. n = 3 independent experiments. Two-tailed t test assuming equal variances. Error bars represent the mean ± standard deviation of the mean.